Cardiomyopathy: Difference between revisions
No edit summary |
No edit summary |
||
Line 29: | Line 29: | ||
[[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]] | [[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]] | ||
<br> | <br> | ||
== <b>2023 ESC Guideline Recommendations </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657 }} </ref>== | == <b>2023 ESC Guideline Recommendations </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657 }} </ref>== |
Revision as of 08:31, 9 November 2023
For patient information click here
Cardiomyopathy | |
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
Cardiomyopathy Microchapters |
Diagnosis |
---|
Treatment |
Guidelines |
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
Case Studies |
Cardiomyopathy On the Web |
American Roentgen Ray Society Images of Cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub,MD; Mahshid Mir, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3], Raviteja Guddeti, M.B.B.S. [4]; Edzel Lorraine Co, DMD, MD[5]
Synonyms and keywords: Myocardiopathy; cardiac muscle disease; heart muscle disease.
Overview
Historical Perspective
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
2023 ESC Guideline Recommendations [1]
Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
Class I |
1. It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the diagnosis and management of cardiomyopathies. (Level of Evidence: C) |
2. Timely and adequate preparation for transition of care from pediatric to adult services, including joint consultations, is recommended in all adolescents with cardiomyopathy. (Level of Evidence: C) |
Recommendations for Diagnostic Work-up in Cardiomyopathies.
Class I |
1. It is recommended that all patients with suspected or established cardiomyopathy undergo systematic evaluation using a multiparametric approach that includes clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging. (Level of Evidence: C) |
2. It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation family tree is created to aid in diagnosis, provide clues to underlying etiology, determine inheritance pattern, and identify at- risk relatives (Level of Evidence: C) |
Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
Class I |
1. (Level of Evidence: C) |
Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
Class I |
1. (Level of Evidence: B) |
Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
Class I |
1. (Level of Evidence: B) |
Recommendations for Computed Tomography and Nuclear Imaging
Class I |
1. (Level of Evidence: B) |
Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
Class I |
Genetic Counselling |
1. (Level of Evidence: B) |
Case Studies
de:Kardiomyopathie nl:Cardiomyopathie no:Kardiomyopati simple:Cardiomyopathy sr:Кардиомиопатија sv:Hjärtmuskelsjukdom
- ↑ Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C; et al. (2023). "2023 ESC Guidelines for the management of cardiomyopathies". Eur Heart J. 44 (37): 3503–3626. doi:10.1093/eurheartj/ehad194. PMID 37622657 Check
|pmid=
value (help).